Norris Medicines Limited (BOM:524414)
India · Delayed Price · Currency is INR 12.87
-1.42 (-9.94%)
At close: Jan 21, 2026
Norris Medicines Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 72.84 | 58.2 | 56.36 | 83.59 | 94.38 | 122.51 | Upgrade | |
Revenue Growth (YoY) | 76.48% | 3.28% | -32.58% | -11.44% | -22.96% | 56.19% | Upgrade |
Cost of Revenue | 48.52 | 35.08 | 26.99 | 35.23 | 57.25 | 89.07 | Upgrade |
Gross Profit | 24.32 | 23.12 | 29.36 | 48.36 | 37.13 | 33.44 | Upgrade |
Selling, General & Admin | 16.35 | 14.13 | 18.21 | 22.98 | 23.38 | 31 | Upgrade |
Other Operating Expenses | 13 | 11.2 | 12.94 | 16.13 | 14.39 | 19.85 | Upgrade |
Operating Expenses | 34.53 | 30.7 | 36.86 | 45.4 | 44.33 | 57.53 | Upgrade |
Operating Income | -10.21 | -7.58 | -7.5 | 2.95 | -7.2 | -24.09 | Upgrade |
Interest Expense | -4.71 | -4.21 | -3.66 | -14.89 | -14.73 | -16.2 | Upgrade |
Interest & Investment Income | 0.18 | 0.18 | 0.18 | 0.12 | 0.12 | 0.13 | Upgrade |
Currency Exchange Gain (Loss) | 0.01 | 0.01 | 0.04 | - | 0.05 | -0.01 | Upgrade |
Other Non Operating Income (Expenses) | -0.07 | -0.19 | -0.04 | -0.12 | -0.09 | 0.23 | Upgrade |
EBT Excluding Unusual Items | -14.79 | -11.78 | -10.98 | -11.93 | -21.85 | -39.93 | Upgrade |
Pretax Income | -14.79 | -11.78 | -10.98 | -11.93 | -21.85 | -39.93 | Upgrade |
Income Tax Expense | 0.59 | 0.59 | 0.89 | 5.56 | 10.79 | 9.69 | Upgrade |
Net Income | -15.39 | -12.37 | -11.87 | -17.49 | -32.63 | -49.62 | Upgrade |
Net Income to Common | -15.39 | -12.37 | -11.87 | -17.49 | -32.63 | -49.62 | Upgrade |
Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 | 10 | Upgrade |
Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 | 10 | Upgrade |
EPS (Basic) | -1.54 | -1.24 | -1.19 | -1.75 | -3.26 | -4.96 | Upgrade |
EPS (Diluted) | -1.55 | -1.24 | -1.19 | -1.75 | -3.26 | -4.96 | Upgrade |
Free Cash Flow | 7.11 | 4.91 | 1.69 | 11.7 | -10.65 | 10.26 | Upgrade |
Free Cash Flow Per Share | 0.71 | 0.49 | 0.17 | 1.17 | -1.06 | 1.03 | Upgrade |
Gross Margin | 33.39% | 39.72% | 52.10% | 57.86% | 39.34% | 27.29% | Upgrade |
Operating Margin | -14.02% | -13.03% | -13.31% | 3.54% | -7.63% | -19.66% | Upgrade |
Profit Margin | -21.13% | -21.26% | -21.06% | -20.93% | -34.58% | -40.50% | Upgrade |
Free Cash Flow Margin | 9.77% | 8.44% | 2.99% | 13.99% | -11.28% | 8.37% | Upgrade |
EBITDA | -5.04 | -2.21 | -1.78 | 9.25 | -0.63 | -17.42 | Upgrade |
EBITDA Margin | -6.91% | -3.80% | -3.17% | 11.07% | -0.67% | -14.22% | Upgrade |
D&A For EBITDA | 5.17 | 5.37 | 5.71 | 6.3 | 6.57 | 6.67 | Upgrade |
EBIT | -10.21 | -7.58 | -7.5 | 2.95 | -7.2 | -24.09 | Upgrade |
EBIT Margin | -14.02% | -13.03% | -13.31% | 3.54% | -7.63% | -19.66% | Upgrade |
Revenue as Reported | 73.57 | 58.82 | 56.64 | 83.73 | 94.64 | 123.04 | Upgrade |
Advertising Expenses | - | 0.06 | - | -0.01 | 0.08 | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.